Open an account

Maia Biotechnology

MAIA · NYSE American

$1.12+$0.05 (+4.67%)TodayMarket closed ·
Prev close $1.07

About MAIA

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Employees
13
Headquarters
Chicago, Illinois
Listed
Jul 28, 2022
Sector
Health Care
Industry
Biotechnology
Website
maiabiotech.com

MAIA key statistics

Market cap
69.15M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
577.08K
Volume
184.54K
Open price
$1.08
High today
$1.13
Low today
$1.07
52 Week high
$3.19
52 Week low
$0.87

Maia Biotechnology (MAIA) at a glance

As of Oct 20, 2026, Maia Biotechnology (MAIA) shares are priced at $1.12, giving the company a market cap of 69.15M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.07 and $1.13. The current price is 4.7% above the day's low and 0.9% below its high.

Volume so far is 184.54K shares, below the average of 577.08K shares a day.

Over the past year Maia Biotechnology has ranged from $0.87 to $3.19, and now sits 11% of the way up that range.

Maia Biotechnology met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1122.

MAIA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 39.0% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.4029
  2. Q4 FY24: reported -$0.12 per share against an estimate of -$0.357
  3. Q1 FY25: reported -$0.16 per share against an estimate of -$0.1836
  4. Q2 FY25: reported -$0.18 per share against an estimate of -$0.2448
  5. Q3 FY25: reported -$0.27 per share against an estimate of -$0.1938
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.1326
  7. Q1 FY26: reported -$0.14 per share against an estimate of -$0.1836
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1122

MAIA news

  • Press releaseGlobe Newswire

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

  • Avi Kapoor

    Crude Oil Surges Over 6%; Target Profit Tops Views

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Dow Dips 900 Points; Best Buy Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releasePRNewswire

    Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

  • Press releasePRNewswire

    Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

  • Press releasePRNewswire

    Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

Similar companies

Companies in the same industry as Maia Biotechnology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.